Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
Quick Look: Generics of Eisai’s Fycompa won approval despite an extended patent running through June, pointing to a possible hydrate-to-anhydrous switch to bypass protection. Whether the strategy will succeed remains unclear, given mixed precedents in recent patent disputes. ----- Generic…
To read the full story
Related Article
- Fycompa Generics Head for Summer Launch as Key Patent Expires
June 23, 2026
- Revolade, Bilanoa See First Generics in June Listing; 3 Final AGs on Roster
June 11, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Sawai Wins Lawsuit over CML Use in Sprycel Generic
May 19, 2025
BUSINESS
- Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
- Leqembi Leads US Anti-Amyloid Market; Eisai Sees Iqlik Reshaping AD Care
August 4, 2026
- Kyorin to Begin Co-Promoting Alesion Eyelid Cream on August 17
August 4, 2026
- Fujifilm, Taiho Forge Strategic Partnership on ADC Manufacturing
August 4, 2026
- Celltrion to Launch 1st Stelara IV Biosimilar on August 20
August 4, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…